Tarpeyo Capsule, Delayed Release
NDC 81749-004
Product Information
Tarpeyo (budesonide) is a NDA-approved product labeled by Calliditas Therapeutics Ab. Budesonide is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It is supplied as a white capsule, delayed release for oral administration. This product entry covers the primary NDC 81749-004 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
CAL10;4MG
Code Structure Chart
Product Details
What is NDC 81749-004?
What are the uses of this product?
What are Active Ingredients of this product?
- BUDESONIDE 4 mg/1 - A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- BUDESONIDE (UNII: Q3OKS62Q6X)
- BUDESONIDE (UNII: Q3OKS62Q6X) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SUCROSE (UNII: C151H8M554)
- STARCH, CORN (UNII: O8232NY3SJ)
- HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4)
- HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)
- HYPROMELLOSE 2910 (3 MPA.S) (UNII: 0VUT3PMY82)
- POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
- CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
- ETHYLCELLULOSE (10 MPA.S) (UNII: 3DYK7UYZ62)
- MEDIUM-CHAIN TRIGLYCERIDES (UNII: C9H2L21V7U)
- OLEIC ACID (UNII: 2UMI9U37CP)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- SHELLAC (UNII: 46N107B71O)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
- METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2) (UNII: 5KY68S2577)
- METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1) (UNII: 74G4R6TH13)
- TALC (UNII: 7SEV7J4R1U)
- DIBUTYL SEBACATE (UNII: 4W5IH7FLNY)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2587883 - budesonide 4 MG Delayed Release Oral Capsule
- RxCUI: 2587889 - TARPEYO 4 MG Delayed Release Oral Capsule
- RxCUI: 2587889 - budesonide 4 MG Delayed Release Oral Capsule [Tarpeyo]
- RxCUI: 2587889 - Tarpeyo 4 MG Delayed Release Oral Capsule
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Budesonide
Budesonide (Entocort EC) is used to treat Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever). Budesonide (Tarpeyo) is used to decrease protein in the urine in patients with primary immunoglobulin A nephropathy (kidney disease that occurs in some people when too much immunoglobin A builds up in the kidney, causing inflammation). Budesonide is in a class of medications called corticosteroids. It works by decreasing inflammation (swelling) in the digestive tract of people who have Crohn's disease or in the kidney of people with nephropathy.
[Learn More]
* Please review the full disclaimer at the bottom of this page.